Agomelatine: mechanism of action and pharmacological profile in relation to antidepressant properties

Autor:	Beatrice Guardiola-Lemaitre, Carmen Muńoz, Philippe Delagrange, C De Bodinat, Elisabeth Mocaer, Mark Millan
Rok vydání:	2014
Předmět:	Pharmacology Agonist medicine.drug_class Glutamate receptor Melatonergic Mechanism of action medicine Serotonin 5-HT2 Receptor Antagonists Agomelatine Antidepressant medicine.symptom Receptor Psychology medicine.drug
Zdroj:	British Journal of Pharmacology. 171:3604-3619
ISSN:	0007-1188
DOI:	10.1111/bph.12720
Popis:	Agomelatine behaves both as a potent agonist at melatonin MT1 and MT2 receptors and as a neutral antagonist at 5-HT2C receptors. Accumulating evidence in a broad range of experimental procedures supports the notion that the psychotropic effects of agomelatine are due to the synergy between its melatonergic and 5-hydroxytryptaminergic effects. The recent demonstration of the existence of heteromeric complexes of MT1 and MT2 with 5-HT2C receptors at the cellular level may explain how these two properties of agomelatine translate into a synergistic action that, for example, leads to increases in hippocampal proliferation, maturation and survival through modulation of multiple cellular pathways (increase in trophic factors, synaptic remodelling, glutamate signalling) and key targets (early genes, kinases). The present review focuses on the pharmacological properties of this novel antidepressant. Its mechanism of action, strikingly different from that of conventional classes of antidepressants, opens perspectives towards a better understanding of the physiopathological bases underlying depression.
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::5cdee1fd06a1559951a7adac465c4f3a https://doi.org/10.1111/bph.12720 Zobrazit plný text záznamu Plný text ve formátu PDF Plný text ve formátu HTML
Nepřihlášeným uživatelům se plný text nezobrazuje	K zobrazení výsledku je třeba se přihlásit.